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Abstract
Background: Alterations in endometrial DNA methylation profile have been proposed as one potential mechanism
initiating the development of endometriosis. However, the normal endometrial methylome is influenced by the
cyclic hormonal changes, and the menstrual cycle phase-dependent epigenetic signature should be considered
when studying endometrial disorders. So far, no studies have been performed to evaluate the menstrual cycle
influences and endometriosis-specific endometrial methylation pattern at the same time.
Results: Infinium HumanMethylation 450K BeadChip arrays were used to explore DNA methylation profiles of
endometrial tissues from various menstrual cycle phases from 31 patients with endometriosis and 24 healthy women. The
DNA methylation profile of patients and controls was highly similar and only 28 differentially methylated regions (DMRs)
between patients and controls were found. However, the overall magnitude of the methylation differences between
patients and controls was rather small (Δβ ranging from –0.01 to –0.16 and from 0.01 to 0.08, respectively, for hypo- and
hypermethylated CpGs). Unsupervised hierarchical clustering of the methylation data divided endometrial samples based
on the menstrual cycle phase rather than diseased/non-diseased status. Further analysis revealed a number of menstrual
cycle phase-specific epigenetic changes with largest changes occurring during the late-secretory and menstrual phases
when substantial rearrangements of endometrial tissue take place. Comparison of cycle phase- and endometriosis-specific
methylation profile changes revealed that 13 out of 28 endometriosis-specific DMRs were present in both datasets.
Conclusions: The results of our study accentuate the importance of considering normal cyclic epigenetic changes in
studies investigating endometrium-related disease-specific methylation patterns.
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Background
DNA methylation, an important epigenetic mechanism
crucial for maintaining tissue-specific gene expression pat-
tern [1, 2], is suggested to be one possible molecular feature
that contributes to the development of many human
diseases, including endometriosis. Deviation from normal
DNA methylation level may lead to alterations in the cellu-
lar microenvironment, affect gene expression and initiate
pathologic processes. During the last decade, several studies
have reported abnormal methylation patterns of selected
genes, e.g. steroidogenic factor 1 [3], progesterone receptor
B [4], oestrogen receptor-β [5], HOXA10 [6–8], HOXA11
[9], COX-2 [10] and aromatase [11], in endometriotic le-
sions and endometria of endometriosis patients. Advance-
ments in microarray technology have now allowed to assess
DNA methylation on a global scale; and to date, already
four studies, though relatively small and using different
array platforms, have suggested genome-wide differences
between endometriosis patients’ endometria and lesions
[12–14] or between endometrial tissues of patients and
controls [15]. Studies on endometriotic lesions or stromal
cells originating from lesions revealed clear evidence of
epigenetic alterations that could be associated with the
disease [12–14]. The issue whether the primary source of
these alterations is endometrial tissue or epigenetic alter-
ations occur during the formation of lesions in abdominal
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cavity in response to changed abdominal environment has
been addressed in the study by Naqvi et al. [15], who evalu-
ated endometrial DNA methylation profile of patients and
controls and suggested that some epigenetic alterations
occur already in the endometria of endometriosis patients.
Furthermore, it has been suggested that alterations on gen-
etic and epigenetic levels during early embryogenesis may
lead to endometriosis development because the fine-tuning
mechanisms responsible for the correct development of the
female genital system are disrupted [16, 17].
Endometrium is a unique tissue undergoing cyclic
breakdown and regeneration, and similarly to other tissues
and cell types [18, 19], has its own distinct DNA methyla-
tion pattern that is influenced by cyclic hormonal changes
[20]. The menstrual cycle phases of the studied women
were not shown in a previous study examining endomet-
rial methylome of endometriosis patients [15]; however, in
the light of the recent knowledge about the significant
impact of menstrual cycle phases on the endometrial
methylome of healthy women [20], it is apparent that
normal cyclic epigenetic signature of endometrial tissue
should be considered when studying endometrial tissue-
related disorders, like endometriosis.
During the past 10 years, a number of studies have been
conducted to find reliable diagnostic biomarkers for endo-
metriosis, unfortunately with little success. The need for
non-invasive or minimally invasive biomarkers is difficult
to underestimate as the average delay between the onset of
symptoms and the surgical diagnosis is almost 7 years [21].
Such biomarkers would enable to avoid the unnecessary
laparoscopy while endometriosis is suspected but not
present and make possible to get the right diagnosis of
endometriosis much earlier. Therefore, the aim of the
current study was to reveal potential epigenetic biomarkers
from endometrial DNA of endometriosis patients’ endome-
tria, from endometriosis centres in Tartu (Estonia) and
Oxford (UK), by considering the menstrual cycle dependent
changes. Furthermore, we aimed to investigate the men-
strual cycle-specific methylation signature to widen the
knowledge about the epigenetic changes occurring during
endometrial growth across the entire menstrual cycle.
Results
Genome-wide DNA methylation analysis of endometrial
tissues from patients with endometriosis and healthy
women
Endometrial samples from 31 endometriosis patients and
24 disease-free women, from menstrual (M, n = 5), prolif-
erative (P, n = 5), early-secretory (ES, n = 8), mid-secretory
(MS, n = 26) and late-secretory (LS, n = 11) menstrual
cycle phases (Table 1), were used for genome-wide DNA
methylation analysis.
The pipeline of the study is given in Fig. 1. Principal
component analysis (PCA) clustering of the normalised
data was used to describe the endometrial DNA methy-
lation profiles of patients with endometriosis and healthy
women (Additional file 1). Approximately 19.6 % of vari-
ation across all studied probes was accounted for in the
first two principal components (12.4 % for PC1 and
7.2 % for PC2), and no significant segregation between
patients and controls was noticed, indicating that the
overall DNA methylation profile between patients and
controls was very similar. Still, if we compared the
methylation profiles of all patients with endometriosis to
healthy women, we found 28 differentially methylated re-
gions (DMRs) (false discovery rate, FDR <0.05, Δβ ranging
from –0.01 to –0.16 and from 0.01 to 0.08) from which 16
were associated to known genes (PI3, SLC43A3,MGAT5B,
MUC4, HIVEP3, FGG, CLCF1, CANT1, LTK, AHRR,
AKR1B1, APEH, CST11, ELOVL4, HBE1 and NEGR1)
(Additional file 2). One of the top-ranking intergenic
DMRs was located on chromosome locus 7p15.2, about
13 kb upstream from HOXA gene cluster.
Unsupervised hierarchical clustering of the same data
(Fig. 2) revealed two main branches that divided endomet-
rial samples based on the menstrual cycle phase rather
than diseased/non-diseased status. The first branch in-
cluded all LS phase samples (n = 11), four out of five M
phase (n = 4) and some MS phase (n = 7) samples, while
the other branch included the majority of samples from
MS (n = 19) phase, ES phase (n = 8), P phase (n = 5) and
one remaining sample from M phase. Therefore, to con-
sider the impact of menstrual cycle on endometriosis-
specific methylation signature, we determined the differ-
ences associated with menstrual cycle phases.
Menstrual cycle-specific DNA methylation signature and
gene ontology (GO) analysis of differentially methylated
regions
As unsupervised hierarchical clustering analysis revealed
no segregation between patients and controls, both
groups were combined (altogether 55 individuals) to find
menstrual cycle phase-specific methylation changes. The
studied individuals were divided into five groups accord-
ing to the menstrual cycle day at the time of biopsy
collection: (1) M (n = 5), (2) P (n = 5), (3) ES (n = 8), (4)
MS (n = 26), and (5) LS phase (n = 11) groups. To assess
the overall methylation pattern characteristic to each
cycle phase, the methylation data of each phase was
compared to other phases. A large number of differen-
tially hypo- and hypermethylated regions (FDR < 0.05)
were noticed when either or both M and LS phases were
involved in comparisons, while only some DMRs were
found in comparisons between P, ES and MS phases
(Table 2, Additional file 3).
As the endometrial tissue growth and degradation during
the menstrual cycle is a continuum where 1-cycle phase
progresses to another, only genes that were differentially
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methylated in adjacent phases (M vs. P, MS vs. LS and LS
vs. M) were included in the downstream analysis. The
complete lists of DMRs were subjected to enrichment
analysis that revealed significant enrichment for multiple
ontology terms (the lists of Gene Ontology—GO terms and
Kyoto Encyclopaedia of Genes and Genomes—KEGG path-
way analysis are outlined in Additional file 4 and 5).
The CpG island (DNA sequence at least 200 bp and
GC content greater than 50 %) hypermethylation in gene
promoter regions has been associated with repression of
gene transcription and hypermethylation of regions next
to CpG islands, island shores (2 kb regions upstream
and downstream of the CpG islands) and shelves (4 kb
regions upstream and downstream of the CpG islands)
with higher gene expression [22]. Therefore, the location
of the differentially methylated CpG sites in relation to
genomic elements such as CpG islands, island shores
and shelves, open sea (all remaining sequence) and gene
structure (promoter region, 5′ UTR, first exon, gene
body, 3′ UTR and intergenic) was analysed to investigate
differential representation of functional categories between
different menstrual cycle phases (Fig. 3). The assessment of
distribution of hypo- and hypermethylated DMRs showed
slight overrepresentation of CpGs located in the open sea
(ranging from 34–66 %) compared to CpGs located within
and next to islands (island, shores and shelves, ranging
from 24–42 %), when the CpG distribution relative to CpG
islands was analysed. The lowest number of CpGs was seen
in shelves (ranging from 4–7 %), whereas higher number
of CpG sites was located within CpG islands (ranging from
5–11 %) and the highest number of CpG sites was located
in shores (ranging from 9–28 %). When the distribution of
CpGs in relation to genes was examined, it was evident
that large proportions of CpGs were located in intergenic
regions and gene bodies (ranging from 38–75 %) and only
a minority of CpGs (ranging from 8–25 %) were in gene
promoter areas. However, when enrichment analysis of
DMRs based on their location (promoter/gene body) was
carried out, no GO terms or KEGG pathways characteristic
to specific menstrual cycle phase were found.
Table 1 General characteristics of the study participants
Microarray study Patients with endometriosis (n = 31) Disease-free women (n = 24)
Estonian patients Oxford patients Estonian controls Oxford controls
(n = 24) (n = 7) (n = 17) (n = 7)
Age (years ± SD) 31.0 ± 4.0 36.0 ± 5.0 30.1 ± 3.2 34.2 ± 6.2
BMI (mean, kg/m2 ± SD) 21.8 ± 3.1 23.6 ± 2.0 23.6 ± 4.2 26.0 ± 4.3
Smoking (n) 0 2 0 0
Stage I–II (n) 16 3 NA NA
Stage III–IV (n) 8 4 NA NA
Only endometrioma (n) 0 4 NA NA
Only peritoneal lesions (n) 14 3 NA NA
Peritoneal lesions together with endometrioma (n) 10 0 NA NA
Menstrual cycle characteristics
Menstrual phase (days 1–5), (n) 0 4 0 1
Proliferative phase (days 6–14), (n) 0 2 0 3
Early-secretory phase (days 15–20),(n) 7 0 0 1
Mid-secretory phase (days 21–23), (n) 8 1 17 0
Late-secretory phase (days 24–28), (n) 9 0 0 2
Validation study Patients with
endometriosis
(n = 15)
Disease-free
women (n = 14)
Age (years ± SD) 31.0 ± 3.39 32.0 ± 2.7
BMI (mean, kg/m2 ± SD) 20.0 ± 3.92 23.1 ± 5.73
Smoking (n) 1 2
Mid-secretory phase (days 21–23), (n) 7 7
Late-secretory phase (days 24–28), (n) 8 7
Stage I–II (n) 13 NA
Stage III–IV (n) 2 NA
NA not applicable
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Fig. 1 Schematic representation of the study design and main steps of the data analysis
Fig. 2 Hierarchical clustering analysis of all endometrial samples included into the study. Sample codes starting with E indicate patients with
endometriosis and H indicates healthy individuals. Samples with the same index number are duplicates
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Next, the complete lists of differentially methylated genes
from each cycle phase comparisons were subjected to Venn
analysis to reveal genes characteristic to specific menstrual
cycle phases (Additional file 6). The results showed 5 hypo-
and 5 hypermethylated genes for M phase and 127 hypo-
and 113 hypermethylated genes for LS phase (central
intersection in the Venn diagram, gene lists are given in
Additional file 7) but no enrichment of specific GO terms
or KEGG pathways was found.
Differentially methylated genes between patients and
controls—effect of menstrual cycle phases
As menstrual cycle phase comparisons revealed several
differences in the methylation pattern, we compared the
lists of endometriosis-specific differentially methylated
genes and regions to the menstrual cycle-specific alter-
ations. Results showed that eight out of 16 differentially
methylated genes found in patients with endometriosis
overlapped with the menstrual cycle-related genes: seven
genes (PI3, SLC43A3, MGAT5B, MUC4, HIVEP3, FGG and
CANT1) from comparison between MS and LS phases and
one gene (LTK) from M to P comparison. The remaining
eight differentially methylated genes—AHRR, AKR1B1,
APEH, CST11, ELOVL4, CLCF1, HBE1 and NEGR1 were
not related to the menstrual cycle changes. From DMRs
that were not related to any genes, five were also found in
the lists of menstrual cycle-specific genes. However, the
top-ranking DMR near the HOXA gene cluster was not
found to be associated with any specific menstrual cycle
phase. To eliminate all potential confounders that may
come from menstrual cycle phase differences, we also com-
pared patients and controls only from MS phase group
because this was the group with the largest number of indi-
viduals (8 patients vs. 17 controls) in our dataset. Interest-
ingly, the MS phase group analysis revealed no DMRs.
Validation of methylation data by direct bisulfite
sequencing
To confirm the results of microarray analysis, four CpG
sites located in the promoter regions (two CpGs from
Table 2 The number of differentially hyper- and hypomethylated DMRs and genes between menstrual cycle phases
DMR and genes
(hyper-/hypomethylated)
M (n = 5) P (n = 5) ES (n = 8) MS (n = 26) LS (n = 11)
M (n = 5) DMR 1009/1775 130/189 363/855 288/368
Genes 632/1066 92/116 254/512 208/222
P (n = 5) DMR 1009/1775 0/0 1/2 3045/1650
Genes 632/1066 0/0 1/0 1768/936
ES (n = 8) DMR 130/189 0/0 0/5 2806/1208
Genes 92/116 0/0 0/3 1015/635
MS (n = 26) DMR 363/855 1/2 0/5 2806/1208
Genes 254/512 1/0 0/3 1616/704
LS (n = 11) DMR 288/368 3045/1650 1727/1050 2806/1208
Genes 208/222 1768/936 1015/635 1616/704
DMR differentially methylated regions, M menstrual phase, P proliferative phase, ES early-secretory phase, MS mid-secretory phase, LS late-secretory phase
Fig. 3 Pie charts of DMRs between different menstrual cycle phases in relation to CpG island and relative to gene. CpG content together with
neighbourhood context was defined as (i) open sea; (ii) island—DNA sequence at least 200 bp and GC content greater than 50 %, island shores—2 kb
regions upstream and downstream of the CpG islands and shelves—2 kb regions upstream and downstream of the CpG island shores and (iii) others
(DMRs with several annotations). Gene context was defined as promoter region (TSS1500—201 to 1500 bp upstream of transcription start site,
TSS200—200 bp to transcription start site and 5′ UTR), the 1st exon of transcript; the gene body; 3′ UTR and NA—non-island and others (DMRs with
several annotations)
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CST11 gene, one from PI3 gene and one from SLC43A3
gene) with differential methylation between patients with
endometriosis and healthy women were selected for
validation analysis by conventional bisulphite Sanger se-
quencing in an extended group of patients and controls
from LS (n = 15) and MS phase (n = 14). The correlation
analysis between microarray and bisulphite sequencing
data showed strong correlation (Pearson’s correlation
coefficient, PCC > 0.85, P < 0.001) for SLC43A3 and
CST11 and moderate correlation (PCC = 0.58, P = 0.07)
for PI3. From four analysed CpG sites, only the CpG
from SLC43A3 gene showed statistically significant dif-
ferential methylation between MS patients and controls
(P = 0.03).
Discussion
To the best of our knowledge, this is the first study
assessing the methylome of endometria of endometriosis
patients and controls using Infinium HumanMethylation
450K BeadChip array and taking into account DNA
methylation changes during the menstrual cycle. The re-
sults of this study suggest that overall endometrial DNA
methylation signature is highly similar between patients
with endometriosis and healthy women but largely influ-
enced by the menstrual cycle phases. Additionally, our
study describes normal endometrial methylome through-
out the menstrual cycle and shows that the largest
changes in epigenetic signature occur in late-secretory
and menstrual phases.
The usability of epigenetic biomarkers in clinical setting
has been accepted and new and simple methodologies
allowing straightforward DNA methylation biomarker
detection in routine diagnostics have already been devel-
oped [23]. Previous endometriosis studies have provided
evidence that the epigenetic changes not only occur in ec-
topic endometriotic lesions but are already present in the
eutopic endometrium of endometriosis patients [15].
Therefore, the combination of eutopic endometrium that
is easily obtainable by the semi-invasive sampling proced-
ure and assessment of DNA methylation markers could
offer an excellent source for epigenetic biomarker discov-
ery. So far, four microarray-based studies in eutopic endo-
metria [15], eutopic/ectopic endometria [12] and primary
stromal cell cultures of eutopic and/or ectopic endometria
[13, 14] have been performed focusing rather on disease
pathogenesis than on clinical usability. Only one study
concentrated on eutopic endometria [15] in the perspec-
tive of using epigenetic markers as potential targets for
therapeutic agents. Despite finding a large number of
differentially methylated genes, the authors concluded that
methylation and demethylation are both common events in
endometrium, making the broad use of therapeutics
affecting the methylation level impractical [15]. In our
study, we tried to find endometrial epigenetic markers
useful for diagnostic purposes. However, the results of our
study indicated that endometrial tissue epigenetic signature
in patients and controls is highly similar and only a few
DMRs were found, indicating that alterations in endomet-
rial methylation pattern are not common in endometriosis.
The lack of substantial differences in endometrial epigen-
etic signature in endometriosis was proposed also by
another study [13], where cultured primary stromal cells
from eutopic and ectopic endometria of endometriosis
patients and healthy women were used. Therefore, we
suggest that endometrial DNA methylation differences do
not provide good biomarkers with acceptable sensitivity
and specificity for discrimination of patients with endo-
metriosis and healthy women.
The further validation of selected CpGs in extended
subsets of patients and controls from MS and LS phase
confirmed differential methylation of CpG in SLC43A3
promoter, however, only between the MS patients and
controls. The SLC43A3 hypermethylation was noticed in
MS phase in our menstrual phase study and also while all
patients were compared to controls, indicating influence
both from disease and menstrual cycle phase. Our results
are supported by the study conducted by Tamaresis et al.
[24] who found that several genes showing differential
methylation in our study (such as AHRR, APEH, ELOV4,
PI3, SLC43A3, MUC4, CANT and CLCF1) revealed also
differential expression between patients and controls from
certain menstrual cycle phases. Interestingly, SLC43A3
was found to be differentially expressed only between MS
phase patients and controls suggesting that small-scale
methylation alterations can probably affect the expression
of this gene. There is only some data about the function of
SLC43A3, but very recently, it was proposed that SLC43A3
is a purine-selective nucleobase transporter [25]. SLC43A3
is expressed during embryogenesis [26] but the possible
role in endometrium or endometriosis development re-
mains to be elucidated.
There is an evidence both on transcriptome [27, 28]
and epigenome levels [20] that endometrial molecular
signature is largely influenced by the menstrual cycle.
The significant impact of menstrual cycle phases to
overall endometrial methylome was confirmed also in
our menstrual cycle phase-specific analysis where we
saw that major epigenetic changes occurred while MS
phase turned to LS phase, by which point, the endomet-
rial tissue has reached its maximal thickness and
secretory capacity, predecidual changes begin in the
stroma and the endometrium is ready for embryo im-
plantation. However, if no implantation takes place, the
degradation processes are initiated. Also, significant
changes were found between LS and M phases, when the
desquamation of the tissue is followed by endometrial shed-
ding and menstruation, and between M and P phases, when
active repair and regeneration processes in endometrial
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tissue are taking place. In light of these results, it is evident
that normal endometrial methylation level fluctuations dur-
ing the menstrual cycle should be taken into account while
searching endometrial biomarkers.
However, we believe that the relevance of epigenetic
markers in the context of disease pathogenesis or menstrual
cycle biology cannot be underestimated. For instance,
one of the most statistically significantly hypomethy-
lated DMRs in patients was an intergenic CpG island
about 13 kb upstream from the HOXA gene cluster.
Whether small but statistically significant differences in
methylation levels could affect gene expression levels is
currently unknown, but previous studies have shown
that the members of HOXA cluster, HOXA10 and
HOXA11 were differentially methylated in stromal cells
obtained from endometriomas [14] and in eutopic en-
dometria from patients [6, 7, 9, 29, 30] compared to
healthy controls, and hypermethylation of the HOXA
genes was accompanied by lower transcript and protein
levels in endometrium of endometriosis patients [6, 9].
In a recent review, Kobayashi et al. [31] assessed aberrantly
expressed genes in endometriosis during the process
of decidualization and normal window of implantation.
Authors suggested that impaired decidualization and dys-
functional expression of genes related to Müllerian embryo-
genesis (like the downstream targets of HOXA10) could be
critical to the development of endometriosis. Also, it was
proposed that DNA methylation of specific genes could
partly explain the link between early exposure to a detri-
mental fetal environment and an increased risk of develop-
ing endometriosis later in life [31]. Furthermore, it has been
proposed that in utero exposure to endocrine disruptor
bisphenol could be one potential cause triggering the
abnormal fetal endometrial cell migration into ectopic
location, as mice exposed in utero to bisphenol exhibited
endometriosis-like phenotype [32]. One of the differentially
methylated genes in our study was AHRR, which shows
increased gene expression in fetal tissues exposed to en-
vironmental or even lower levels of bisphenol [33]. It has
been proposed that developmental exposure to environ-
mental toxins may induce irregular methylation patterns
and thereby permanently alter the expression of AHRR
[34]. The relevance of AHRR methylation to theory of
endometrial origin of endometriosis is intriguing and worth
further examination.
Some limitations of our study should be highlighted.
Although analysed samples covered the whole menstrual
cycle, the size of some study groups (e.g. M and P phases)
was rather small. Moreover, the limited number of samples
from particular menstrual cycle phases restricted the possi-
bility to compare patients and controls from each phase
separately. Furthermore, histological endometrial dating
was available only for healthy volunteers from MS group
and therefore, as the self-reported day of menstrual cycle is
less accurate for phase dating, it could have some negative
impacts on menstrual cycle phase-specific analysis.
Conclusions
The results of this study demonstrated that endometrial
DNA methylation profile of women with and without
endometriosis was highly similar and thus, epigenetic
modifications in endometria are probably not the pri-
mary source contributing to endometriosis development.
Although some DMRs between patients with endometri-
osis and controls were found, the magnitude of the
methylation differences was too small to enable discrim-
ination between patients and controls. The findings of
this study provide new knowledge about the normal epi-
genetic changes occurring across the menstrual cycle
phases and accentuate the importance of considering
normal cyclic epigenetic changes when looking for dis-
ease specific endometrial DNA methylation changes.
Methods
Ethics statement
The study was approved by the Research Ethics Committee
of the University of Tartu (219/M-15) and written informed
consent was obtained from all participants. Tissues from
cases and controls from Oxford originated from the
ENDOX study, which was approved by the NRES Commit-
tee South Central-Oxford Research Ethics Committee (09/
H0604/58).
Study subjects and tissue processing
Altogether, 31 patients and 24 disease-free women were
recruited into the microarray study (Table 1). General
characteristics, such as age and BMI were similar between
patients and all controls (Student’s t test, P > 0.05).
Endometrial tissue samples were collected from 31
patients undergoing laparoscopy at the Tartu University
Hospital Women’s Clinic, Elite Clinic (Tartu, Estonia,
n = 24) and John Radcliffe Hospital (Oxford, UK, n = 7). In
all cases, the diagnosis was histologically confirmed and
disease severity was determined according to the American
Society for Reproductive Medicine revised classification
system [35]. All patients were in reproductive age, having
received no hormonal medication during the previous
3 months before laparoscopic surgery and had a regular
menstrual cycle (28 ± 5 days). Self-reported menstrual cycle
day was used to estimate cycle phase.
Control group consisted of 24 disease-free women from
whom 17 were self-reported healthy volunteers (Elite
Clinic, Tartu and Nova Vita Clinic, Tallinn, Estonia) and
seven were undergoing laparoscopy for pelvic pain, subfer-
tility or tubal sterilisation and confirmed to be endometri-
osis free (Oxford control group). Healthy volunteers were
all in reproductive age, had not used hormonal medication
at least 3 months before the recruitment, had regular
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menstrual cycle (28 ± 5 days), had normal serum levels of
progesterone, prolactin and testosterone, normal vaginal
ultrasound, negative screening results for sexually transmit-
ted diseases and no presence of endometriosis or polycystic
ovary syndrome. Endometrial biopsies for the Estonian con-
trols were collected under local anaesthesia, and menstrual
cycle dating was confirmed by combining menstrual cycle
history, luteinizing hormone (LH) peak (estimated by the
BabyTime® hLH urine cassette, Pharmanova), vaginal ultra-
sound and by the histological evaluation of biopsy accord-
ing to the Noyes’ criteria [36]. The menstrual cycle phases
for Oxford controls were estimated according to their
self-reported menstrual cycle day.
For validation study, an extended group of patients
and controls from LS (n = 15) and MS phases (n = 14)
was used, and in addition to endometrial samples from
microarray study (n = 11), further endometrial samples
from patients with endometriosis from LS phase (n = 4)
and MS phase (n = 3) and healthy controls (n = 8) from
LS phase and MS (n = 3) phase were collected (Table 1).
Endometrial biopsy samples from patients and con-
trols were collected using an endometrial suction cath-
eter (Pipelle, Laboratoire CCD).
Pre-processing and normalisation of the methylation
microarray data
DNA bisulfite treatment using EZ DNA Methylation kits
(Zymo Research) and DNA hybridization to Infinium
HumanMethylation 450K BeadChip were performed at
USC Epigenome Center (Los Angeles, CA) according to
the manufacturer’s specifications.
Microarray data from Estonian and Oxford datasets
were combined for the data analysis. The raw intensity
files were imported into the R statistical computing
environment using Bioconductor package minfi [37].
The methylation value (beta value) for each probe was
then computed into beta value using Illumina’s formula
M/(M +U + 100), where M and U represent methylated
and unmethylated signal intensities, respectively [38].
The delta beta (Δβ) value was calculated as difference in
β-values between the two groups. Methylation values
ranged from 0, fully unmethylated, to 1, fully methylated
cytosine. Multiple quality control measures were then
applied to filter out unwanted probes. Probes containing
SNP sites (n = 65), probes with the detection P value >0.01
in more than one sample (n = 11055) and probes with the
beadcount <3 in at least 5 % of the samples (n = 2074)
were removed. The remaining 461,286 probes were
normalised for adjusting type1 and type2 probes using
Beta-Mixture Quantile (BMIQ) normalisation method
[39]. Finally, the batch effect was corrected using ComBat
normalisation method [40]. The preprocessing, quality
control and batch effect analyses were performed using
the Bioconductor ChAMP package [41]. Two Estonian
samples and all Oxford samples were run as duplicates
(technical replicates). The Pearson correlation coefficient
was >0.99 for all replicates, confirming a good level of
technical reproducibility. The duplicate beta values were
averaged and used for further data analysis. PCA and
unsupervised hierarchical clustering were performed as
a part of quality control and to provide a visual over-
view of methylation differences between the samples.
All analyses were performed using statistical computing
environment R.
Identification of DMRs
DMRs were identified using ‘seqlm’ package (https://
github.com/raivokolde/seqlm) in the R environment,
utilising MDL-based approach described earlier [18]. The
Benjamini–Hochberg FDR was calculated for each probe,
with an FDR corrected P value <0.05 used to define DMRs.
The DMR analyses were performed to assess the differ-
ences between (i) endometria of healthy and endometriosis
patients and (ii) menstrual cycle phases. In order to get
optimal DMRs, we limited our search in regions where
distance between at least three consecutive probes was
≤500 bp. Venn analysis, to determine overlaps between
DMR genes, was performed using the web-based program
VENNY 2.0 (http://bioinfogp.cnb.csic.es/tools/venny/).
Validation of methylation array data by direct bisulfite
sequencing
Four CpGs with differential methylation, two from
CST11 gene (cg06197930, cg12480562), one from PI3
gene (cg19931348) and one from SLC43A3 gene
(cg13046608) were selected for validation analysis. Bi-
sulfite modification of the endometrial DNA samples
(500 ng each) was carried out with the EZ DNA
Methylation-Gold™ kit (Zymo Research) according to
the manufacturer’s specifications. PCR primers for the
bisulfite-treated DNA were designed using MethPrimer
[42]. PCR conditions and list of primers are provided in
Additional file 8. The sequencing results were analysed
as described in [43] and using Mutation Surveyor soft-
ware (Softgenetics, State College, PA, USA).
Functional enrichment analysis
A web-based tool g: Profiler was utilised to query genes
from DMRs for GO category and KEGG (Kyoto
Encyclopaedia of Genes and Genomes) pathway enrich-
ment (http://biit.cs.ut.ee/gprofiler/) [44]. The FDR P
value <0.05 was considered statistically significant.
Availability of supporting data
The datasets supporting the results of this article have
been deposited at NCBI Gene Expression Omnibus data
repository with accession number GSE73950.
Saare et al. Clinical Epigenetics  (2016) 8:2 Page 8 of 10
Additional files
Additional file 1: Principal component analysis describing DNA
methylation data across all studied endometrial samples. The large
dots and triangles mark overlapping samples. (TIF 852 kb)
Additional file 2: Differentially methylated regions between women
with endometriosis and healthy women. The methylation data of all
patients was compared to controls. Menstrual cycle day has not been
taken into account. (XLSX 15 kb)
Additional file 3: Differentially methylated regions between
different menstrual cycle phases. The methylation data of each
menstrual cycle phase was compared to other phases. (XLSX 2676 kb)
Additional file 4: Functional annotation clustering of hypo- and
hypermethylated genes in endometrial tissue using g:profiler
bioinformatics tool. The complete lists of DMRs between different
menstrual cycle phases was used to create the lists of Gene Ontology
terms. (XLSX 27 kb)
Additional file 5: Pathway analysis of hypo- and hypermethylated
genes in endometrial tissue using g:profiler bioinformatics tool. The
complete lists of DMRs between different menstrual cycle phases was
used to create the list of Kyoto Encyclopedia of Genes and Genomes
(KEGG) pathways. (XLSX 12 kb)
Additional file 6: Venn diagrams of differentially methylated genes.
Diagrams show the total number of hypo- and hypermethylated genes
identified in each comparison. (TIF 3142 kb)
Additional file 7: Menstrual cycle phase specific genes. The list of
late-secretory and menstrual phase specific hyper- and hypomethylated
genes. (XLSX 28 kb)
Additional file 8: PCR primers used in the methylation validation
analysis. PCR primers for the bisulfite-treated DNA were designed using
MethPrimer[42]. (XLSX 9 kb)
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